These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2288502)

  • 1. [New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
    Ribeiro L; Kohn IJ
    Arq Bras Cardiol; 1990 Mar; 54(3):177-8. PubMed ID: 2288502
    [No Abstract]   [Full Text] [Related]  

  • 2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H; Weidmann P
    Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
    Prager R
    Wien Med Wochenschr Suppl; 1989; 105():17-20. PubMed ID: 2694627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
    Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
    Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
    Behrens-Baumann W; Morawietz A; Thiery J; Creutzfeldt C; Seidel D
    Lens Eye Toxic Res; 1989; 6(1-2):331-7. PubMed ID: 2488025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
    Prat H; Román O; Pino E
    Rev Med Chil; 1999 Mar; 127(3):286-94. PubMed ID: 10436712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
    Ohri SK; Keane PF; Swift I; Sackier JM; Williamson RC; Thompson GR; Wood CB
    Am J Gastroenterol; 1989 Jul; 84(7):740-3. PubMed ID: 2741883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hydroxymethylglutaryl CoA reductase inhibitors. A new group of substances for lowering a high cholesterol level].
    Uhl D
    Med Monatsschr Pharm; 1988 Oct; 11(10):326-30. PubMed ID: 3185357
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
    Darioli R; Bovet P; Brunner HR; Bercher L
    Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
    Wenke K; Thiery J; Meiser B; Arndtz N; Seidel D; Reichart B
    Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
    Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic use of lovastatin in the treatment of hypercholesterolemia.
    Illingworth DR
    Clin Ther; 1994; 16(1):2-26; discussion 1. PubMed ID: 8205598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM; Katyal A
    Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
    Geisel J; Oette K; Burrichter H
    Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
    Weber C; Erl W; Weber KS; Weber PC
    J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin alone and in combination for treatment of primary hypercholesterolemia.
    Stein EA; Lamkin GE; Bewley DZ
    Prog Clin Biol Res; 1988; 255():281-93. PubMed ID: 3340642
    [No Abstract]   [Full Text] [Related]  

  • 19. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
    Sartor G; Katzman P; Eizyk E; Kalén J; Nilsson A; Ugander L; Ursing D
    Int J Clin Pharmacol Ther; 1995 Jan; 33(1):3-6. PubMed ID: 7711988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
    Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
    Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.